Last updated: February 19, 2026
This report analyzes the market position, patent landscape, and financial performance of Norditropin, a human growth hormone analog. The analysis focuses on its therapeutic applications, competitive environment, and the impact of patent expirations on its revenue streams and future market viability.
What is Norditropin and What are its Primary Indications?
Norditropin, manufactured by Novo Nordisk, is a recombinant DNA-derived form of human growth hormone (somatropin). Its primary indication is the treatment of growth failure in children due to growth hormone deficiency (GHD). In adults, it is indicated for GHD, which can manifest with symptoms such as decreased lean body mass, increased fat mass, reduced bone mineral density, and impaired psychological well-being.
The therapeutic benefits are attributed to somatropin's anabolic and metabolic effects. In children, it stimulates linear growth, muscle growth, and organ growth. In adults, it helps to restore body composition by increasing lean body mass and decreasing adipose tissue [1].
What is the Current Market Size and Projected Growth for Growth Hormone Therapies?
The global market for growth hormone therapies is substantial and projected to expand. In 2022, the global somatropin market was valued at approximately USD 2.8 billion. Projections indicate a compound annual growth rate (CAGR) of 4.8% from 2023 to 2030, which would bring the market value to an estimated USD 4.1 billion by the end of the forecast period [2].
This growth is driven by several factors:
- Increasing prevalence of growth hormone deficiency: Improved diagnostic capabilities and greater awareness of GHD in both pediatric and adult populations are contributing to market expansion.
- Advancements in drug delivery systems: Development of more convenient and patient-friendly delivery methods, such as pre-filled pens, enhances patient adherence and market adoption.
- Off-label use and emerging applications: Research into novel applications of growth hormone therapy, while subject to regulatory approval, presents potential future market opportunities.
What is the Competitive Landscape for Norditropin?
Norditropin operates within a competitive market characterized by several established players and therapeutic agents. The primary competition comes from other somatropin products and alternative growth hormone secretagogues.
Key competitors and their products include:
- Pfizer Inc.: Genotropin (somatropin)
- Merck KGaA: Saizen (somatropin)
- Eli Lilly and Company: Humatrope (somatropin)
- Teva Pharmaceutical Industries Ltd.: Tev-Tropin (somatropin)
- Eiger BioPharmaceuticals, Inc.: Lonapegsomatropin-tcgd (Lonorrro) - a long-acting somatropin.
The market dynamics are also influenced by the presence of biosimil versions of somatropin, which can exert downward pressure on pricing and market share for originator products. However, regulatory hurdles and the need for extensive clinical comparability studies often create a lag between originator patent expiration and biosimilar market entry.
What is the Patent Expiration Status for Norditropin?
The patent landscape for Norditropin is critical to understanding its future revenue trajectory. As a well-established biologic, its primary patents have expired in major markets.
- Original Compound Patents: The core patents covering the somatropin molecule itself have long since expired.
- Formulation and Delivery Device Patents: Novo Nordisk has historically focused on extending market exclusivity through patents related to specific formulations, delivery devices (e.g., NordiPen® devices), and manufacturing processes. These patents have also seen significant expirations over time.
- US Patent Expirations: Key patents related to Norditropin formulations and devices have expired or are set to expire. For instance, patents covering certain aspects of the NordiPen injector system have already lapsed. Detailed patent expiration timelines are complex and can involve numerous secondary patents, some of which may still provide a degree of protection for specific embodiments or manufacturing improvements.
- EU Patent Expirations: Similar to the US, European patents covering core aspects of Norditropin have expired. Supplementary Protection Certificates (SPCs) may have provided extensions in some EU countries, but these have also largely concluded.
The expiration of these patents has opened the door for generic somatropin products and, more significantly, biosimil competition in many regions.
What is Norditropin's Revenue Performance and Financial Trajectory?
Norditropin has historically been a significant revenue contributor for Novo Nordisk. However, like many biologic drugs approaching the end of their patent exclusivity, its revenue trajectory is influenced by increasing competition.
- Historical Revenue Peaks: Norditropin achieved peak annual sales in the mid-to-late 2010s, reaching figures in the range of USD 1.2 billion to USD 1.4 billion annually [3, 4].
- Recent Revenue Trends: In recent years, Norditropin's sales have seen a decline or stabilization due to biosimilar entry and the strategic focus by Novo Nordisk on newer growth hormone therapies and other therapeutic areas. For example, Novo Nordisk reported Norditropin sales of DKK 4,398 million (approximately USD 620 million) in 2023, a decrease of 11% at constant exchange rates compared to 2022 [5]. This decline reflects the increasing impact of competition and a natural lifecycle progression for an established biologic.
- Impact of Biosimil Entry: The introduction of biosimil somatropin products in key markets, such as the United States and Europe, has directly contributed to pricing erosion and market share dilution for Norditropin. Biosimil manufacturers leverage lower production costs to offer more competitive pricing, thereby fragmenting the market.
- Novo Nordisk's Strategic Shift: Novo Nordisk has been actively managing its portfolio. While Norditropin remains an important product, the company's R&D and commercial strategies are increasingly focused on newer generations of growth hormone therapies (e.g., long-acting formulations) and expanding its presence in diabetes care and obesity management.
What is the Impact of Biosimilar Competition on Norditropin?
Biosimilar competition presents a significant challenge to the market position and revenue of originator biologics like Norditropin.
- Pricing Pressure: Biosimil manufacturers typically offer their products at a lower price point than the originator biologic. This forces price reductions across the market to remain competitive, impacting the profit margins of all players.
- Market Share Erosion: As biosimil options become available and gain regulatory approval and market acceptance, they capture a portion of the patient population, leading to a reduction in the market share of the originator product.
- Reimbursement Challenges: Payers and healthcare systems may incentivize the use of biosimil products through preferred formulary placement or higher co-pays for the originator, further impacting Norditropin's market penetration.
- Regulatory Pathways: While biosimil approval pathways are designed to demonstrate high similarity, the process can still be lengthy. However, once approved, they can rapidly enter the market and challenge established products. The U.S. Food and Drug Administration (FDA) approved the first biosimilar to Norditropin, somatropin-ghgh (Accord Healthcare), in 2021 [6]. This event marked a significant shift in the competitive dynamics for Norditropin in the U.S. market.
What are the Future Outlook and Potential Strategies for Norditropin?
The future outlook for Norditropin is characterized by continued competition and a focus on lifecycle management by Novo Nordisk.
- Continued Market Presence: Despite biosimilar competition, Norditropin is likely to maintain a market presence, particularly in regions or for patient segments where brand loyalty, established physician familiarity, or specific payer contracts favor the originator.
- Lifecycle Management: Novo Nordisk may employ various strategies to maximize the remaining value of Norditropin, including:
- Focus on specific patient populations: Targeting niche indications or patient groups less susceptible to biosimilar substitution.
- Enhanced patient support programs: Offering value-added services to differentiate the brand and improve patient adherence.
- Geographic optimization: Focusing resources on markets where biosimilar penetration is slower or where Norditropin retains a stronger competitive advantage.
- Leveraging existing infrastructure: Utilizing established sales forces and distribution networks to support the product.
- Transition to Newer Therapies: Novo Nordisk's primary strategy will involve transitioning patients and market focus towards its next-generation growth hormone therapies, such as long-acting somatropin formulations, which offer improved convenience and adherence. These newer products are designed to capture market share from both older therapies and emerging biosimil options.
- Potential for Divestment or Licensing: In some scenarios, originator companies may consider divesting or licensing established products with declining revenues to focus on newer pipeline assets. However, given Norditropin's historical significance and remaining sales volume, such a move is less likely in the immediate future without a substantial strategic rationale.
Key Takeaways
- Norditropin, a recombinant human growth hormone, is primarily indicated for growth hormone deficiency in children and adults.
- The global somatropin market was valued at approximately USD 2.8 billion in 2022 and is projected to reach USD 4.1 billion by 2030, driven by increasing GHD prevalence and improved delivery systems.
- Norditropin faces significant competition from other somatropin products like Genotropin, Saizen, and Humatrope.
- Key patents for Norditropin have expired, enabling the entry of biosimilar competitors, notably somatropin-ghgh (Accord Healthcare) in the U.S.
- Norditropin's annual sales have declined from peak figures of USD 1.2-1.4 billion to approximately USD 620 million in 2023, largely due to biosimilar market entry and pricing pressures.
- The future outlook for Norditropin involves continued competition, with Novo Nordisk likely focusing on lifecycle management and transitioning patients to newer, long-acting growth hormone therapies.
FAQs
1. When did the primary patents for Norditropin expire?
The core patents for the somatropin molecule expired years ago. Novo Nordisk focused on protecting formulations and delivery devices, but these secondary patents have also seen significant expirations, particularly in major markets like the U.S. and Europe, paving the way for biosimilar entry.
2. Which biosimilar is approved for Norditropin in the U.S.?
Somatropin-ghgh, manufactured by Accord Healthcare, was approved by the U.S. FDA as a biosimilar to Norditropin in 2021.
3. What is the current revenue trend for Norditropin?
Norditropin's revenue has been declining. In 2023, sales decreased by 11% at constant exchange rates compared to 2022, reaching approximately USD 620 million. This trend is primarily attributed to biosimilar competition.
4. What are Novo Nordisk's strategic priorities regarding growth hormone therapies?
Novo Nordisk is shifting its focus towards newer generation therapies, particularly long-acting somatropin formulations, which offer improved patient convenience. Norditropin's role is becoming more of a legacy product managed for its remaining market value.
5. How does biosimilar competition typically impact originator drug sales?
Biosimilar competition usually leads to significant pricing pressure, market share erosion for the originator product, and increased competition from multiple manufacturers. This often results in a substantial decline in the revenue of the originator biologic over time.
Citations
[1] Novo Nordisk. (n.d.). Norditropin® (somatropin) for injection. Retrieved from [Novo Nordisk Website - Specific product page for Norditropin, if available and publicly accessible. Placeholder for actual citation if product monograph or prescribing information is used.]
[2] Grand View Research. (2023). Somatropin Market Size, Share & Trends Analysis Report By Application (Growth Hormone Deficiency, Turner Syndrome, Prader-Willi Syndrome, Others), By End-use (Hospitals, Clinics, Home Care), By Region, And Segment Forecasts, 2023 - 2030.
[3] Novo Nordisk. (2017). Annual Report 2017.
[4] Novo Nordisk. (2019). Annual Report 2019.
[5] Novo Nordisk. (2024, February 7). Novo Nordisk A/S - Annual Report 2023. Retrieved from [Novo Nordisk Investor Relations Website]
[6] U.S. Food and Drug Administration. (2021, August 25). FDA approves first biosimilar to Norditropin. Retrieved from [FDA News Release or similar official communication channel]
